RxDoctor Payments Data

Lisa Young

Acute Care · Cleveland, OHNPI 1720275092

Payments from drug & device makers

$1,316in general payments, 2019–2025

Across 53 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$511
  • Intuitive Surgical$455
  • AstraZeneca$159
  • Lilly USA, LLC$51
  • United Therapeutics Corporation$33
  • Otsuka America Pharmaceutical, Inc.$29
  • plus $78 from 4 others

What the payments were for

  • Travel & lodging$45535%
  • Food & beverage$84264%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,316 in reported general payments places this provider in the 80th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$21,091
Medicare patients
164
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin105$99,312
FarxigaDapagliflozin Propanediol33$33,084
KerendiaFinerenone25$17,041
EliquisApixaban17$11,365
Nifedipine ErNifedipine184$3,805
Scopolamine13$2,050
Bumetanide51$1,953
Mycophenolate Mofetil12$877
Allopurinol108$571
Doxazosin Mesylate33$550
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$548
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$523
Potassium Chloride52$519
Furosemide114$508
Atorvastatin Calcium27$367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$159$33,08433 claims
BayerKerendia$511$17,04125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,101 acute care providers in Ohio.

Other acute care in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →